Familial medullary thyroid carcinoma:: Clinical variability and low aggressiveness associated with RET mutation at codon 804

被引:79
作者
Lombardo, F
Baudin, E
Chiefari, E
Arturi, F
Bardet, S
Caillou, B
Conte, C
Dallapiccola, B
Giuffrida, D
Bidart, JM
Schlumberger, M
Filetti, S
机构
[1] Inst Gustave Roussy, Dept Biol Clin, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Nucl Med Serv, F-94805 Villejuif, France
[3] Univ Catanzaro, Dipartimento Med Sperimentale & Clin G Salvatore, I-88100 Catanzaro, Italy
[4] Ist CSS Mendel, I-00161 Rome, Italy
[5] Ctr Francois Baclesse, Nucl Med Serv, F-14076 Caen, France
[6] Osped San Luigi, Div Med Oncol, I-95123 Catania, Italy
[7] Univ Roma La Sapienza, Dipartimento Sci Clin, I-00161 Rome, Italy
关键词
D O I
10.1210/jcem.87.4.8403
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sixty-one heterozygotes harboring the germline V804L mutation of the RET protooncogene were identified in five independent families. A total of 31 subjects underwent surgery. Histology identified C cell hyperplasia in 30 cases, isolated in 12 and associated with medullary thyroid carcinoma (MTC) in 18. Six patients with MTC had lymph node metastases. Among the 14 patients with basal detectable calcitonin (CT) level, 12 had MTC and 2 had isolated C cell hyperplasia. In most individuals carrying 804 RET mutation, C cell disease displayed late onset and an indolent course; a pentagastrin test was negative in the majority of heterozygotes during the first 2 decades and was positive in only half of them during the third and fourth decades of life. Interestingly, concomitant somatic M918T was detected in a 12-yr-old girl with MTC and was likely to be responsible for both the early clinical appearance and the aggressiveness of the disease. Our data show that in these gene carriers, surgery may be postponed to the fourth decade of life or until the pentagastrin stimulation test becomes positive. Indeed, our data should be confirmed on a larger series of V804L carriers, but may offer a balanced strategy to keep under control and prevent development of the full disease phenotype.
引用
收藏
页码:1674 / 1680
页数:7
相关论文
共 28 条
[1]   PENTAGASTRIN STIMULATION TEST AND EARLY DIAGNOSIS OF MEDULLARY-THYROID CARCINOMA USING AN IMMUNORADIOMETRIC ASSAY OF CALCITONIN - COMPARISON WITH GENETIC SCREENING IN HEREDITARY MEDULLARY-THYROID CARCINOMA [J].
BARBOT, N ;
CALMETTES, C ;
SCHUFFENECKER, I ;
SAINTANDRE, JP ;
FRANC, B ;
ROHMER, V ;
JALLET, P ;
BIGORGNE, JC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (01) :114-120
[2]   A RET double mutation in the germline of a kindred with FMTC [J].
Bartsch, DK ;
Hasse, C ;
Schug, C ;
Barth, P ;
Rothmund, M ;
Höppner, W .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2000, 108 (02) :128-132
[3]  
BOLINO A, 1995, ONCOGENE, V10, P2415
[4]   A large family with hereditary MTC: Role of RET genetic analysis in differential diagnosis between MEN 2A and FMTC [J].
Chiefari, E ;
Chiarella, R ;
Crocetti, U ;
Tardio, B ;
Arturi, F ;
Russo, D ;
Trischitta, V ;
Filetti, S ;
Zingrillo, M .
HORMONE AND METABOLIC RESEARCH, 2001, 33 (01) :52-56
[5]   Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma [J].
Chiefari, E ;
Russo, D ;
Giuffrida, D ;
Zampa, GA ;
Meringolo, D ;
Arturi, F ;
Chiodini, I ;
Bianchi, D ;
Attard, M ;
Trischitta, V ;
Bruno, R ;
Giannasio, P ;
Pontecorvi, A ;
Filetti, S .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1998, 21 (06) :358-364
[6]  
Eng C, 1996, CANCER RES, V56, P2167
[7]   RET proto-oncogene in the development of human cancer [J].
Eng, C .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :380-393
[8]   The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 - International RET mutation consortium analysis [J].
Eng, C ;
Clayton, D ;
Schuffenecker, I ;
Lenoir, G ;
Cote, G ;
Gagel, RF ;
vanAmstel, HKP ;
Lips, CJM ;
Nishisho, I ;
Takai, SI ;
Marsh, DJ ;
Robinson, BG ;
FrankRaue, K ;
Raue, F ;
Xue, FY ;
Noll, WW ;
Romei, C ;
Pacini, F ;
Fink, M ;
Niederle, B ;
Zedenius, J ;
Nordenskjold, M ;
Komminoth, P ;
Hendy, GN ;
Gharib, H ;
Thibodeau, SN ;
Lacroix, A ;
Frilling, A ;
Ponder, BAJ ;
Mulligan, LM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (19) :1575-1579
[9]   FAMILIAL MEDULLARY-THYROID CARCINOMA WITHOUT ASSOCIATED ENDOCRINOPATHIES - A DISTINCT CLINICAL ENTITY [J].
FARNDON, JR ;
LEIGHT, GS ;
DILLEY, WG ;
BAYLIN, SB ;
SMALLRIDGE, RC ;
HARRISON, TS ;
WELLS, SA .
BRITISH JOURNAL OF SURGERY, 1986, 73 (04) :278-281
[10]  
Fattoruso O, 1998, HUM MUTAT, pS167